MENU
+Compare
CANF
Stock ticker: ASE
AS OF
Jan 17 closing price
Price
$1.55
Change
-$0.04 (-2.52%)
Capitalization
10.11M

CANF Can-Fite BioPharma Ltd Forecast, Technical & Fundamental Analysis

a developer of biopharmaceuticals for treatment of autoimmune diseases and cancers

Industry Biotechnology
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CANF with price predictions
Jan 14, 2025

Momentum Indicator for CANF turns positive, indicating new upward trend

CANF saw its Momentum Indicator move above the 0 level on December 31, 2024. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CANF's RSI Indicator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CANF just turned positive on December 26, 2024. Looking at past instances where CANF's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CANF advanced for three days, in of 211 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 39 cases where CANF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CANF broke above its upper Bollinger Band on January 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.812) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). CANF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (12.300) is also within normal values, averaging (263.573).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CANF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CANF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CANF is expected to report earnings to rise 767.00% to -8 cents per share on March 23

Can-Fite BioPharma Ltd CANF Stock Earnings Reports
Q4'22
Est.
$-0.09
Q3'22
Beat
by $0.08
Q2'22
Beat
by $0.04
Q1'22
Beat
by $0.14
The last earnings report on November 25 showed earnings per share of 0 cents, beating the estimate of -9 cents. With 78.87K shares outstanding, the current market capitalization sits at 10.11M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals for treatment of autoimmune diseases and cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
26 Ben Gurion Street
Phone
+972 39241114
Employees
5
Web
http://www.canfite.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

CANF and Stocks

Correlation & Price change

A.I.dvisor tells us that CANF and LGVN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CANF and LGVN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-2.52%
LGVN - CANF
31%
Poorly correlated
-3.41%
RNA - CANF
31%
Poorly correlated
+2.23%
GBIO - CANF
28%
Poorly correlated
+0.18%
ATNM - CANF
26%
Poorly correlated
+14.75%
ARWR - CANF
25%
Poorly correlated
+2.84%
More